Saphenous vein graft disease treated with the Wiktor Hepamed stent: procedural outcome, in-hospital complications and six-month angiographic follow-up

Can J Cardiol. 2000 Apr;16(4):473-80.

Abstract

Objectives: To evaluate the effectiveness of electively placed heparin-coated stents in the treatment of coronary saphenous vein bypass grafts with de novo lesions less than 15 mm in diameter in a prospective study with all eligible consecutive patients presenting to Middelheim Hospital, Antwerp, Belgium between September 1997 and August 1998.

Patients and methods: Fifty patients with 53 lesions were studied. Anginal class, risk factors, quantitative coronary angiographic measurements pre- and postprocedure, procedural outcome, in-hospital events, clinical status on discharge, and six-month clinical and angiographic follow-up (in 48 patients) were recorded. All patients received acetylsalicylic acid and ticlopidine, unless known intolerance was present.

Results: On average, 1.1 stents/patient were placed in very old saphenous vein grafts (11. 7+/-3.9 years). Procedural success was 98%. Only two non-Q wave myocardial infarctions (MIs) occurred, with no Q-wave MIs and no deaths during hospital stay. Length of hospital stay was short (2. 4+/-1.7 days), and 96% of patients were free of angina on discharge. At six-months' follow-up, two patients had died, one of whom died of a noncardiac cause. One patient suffered a non-Q wave MI. At six months, 86% of patients were free from angina. Minimal luminal diameter decreased from 1.14 mm before to 3.33 mm after stenting and to 2.52 mm at six months. Restenosis was present in 22% of patients (21.6% of lesions).

Conclusions: In a selected population with coronary saphenous vein bypass graft disease, Wiktor heparin-coated stents can be delivered with an excellent periprocedural outcome. Six-month outcome appears favourable with a low recurrence of angina (18%) and a low rate of angiographic restenosis (21.6%).

MeSH terms

  • Aged
  • Aspirin / therapeutic use
  • Coronary Angiography
  • Coronary Artery Bypass*
  • Female
  • Fibrinolytic Agents / therapeutic use
  • Follow-Up Studies
  • Graft Occlusion, Vascular / therapy*
  • Heparin / administration & dosage
  • Humans
  • Length of Stay
  • Male
  • Postoperative Complications / epidemiology
  • Prospective Studies
  • Recurrence
  • Saphenous Vein / transplantation*
  • Stents* / adverse effects
  • Ticlopidine / therapeutic use
  • Time Factors
  • Treatment Outcome

Substances

  • Fibrinolytic Agents
  • Heparin
  • Ticlopidine
  • Aspirin